Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.
Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center
Advertisement
Articles by Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Role of Combination I/O in Advanced Endometrial Cancer (EC)Published: April 14th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5